Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:10283
Name prostate cancer
Definition A male reproductive organ cancer that is located_in the prostate.
Source DiseaseOntology.org
Alt Ids DOID:514
Path disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 wild-type SAR405838 prostate cancer sensitive detail...
PTEN del VS-5584 prostate cancer sensitive detail...
PTEN del Rucaparib prostate cancer sensitive detail...
PIK3CA mutant MEN1611 prostate cancer sensitive detail...
PIK3CA Q546R MEN1611 prostate cancer sensitive detail...
PTEN del MEN1611 prostate cancer sensitive detail...
PTEN del Pictilisib + Vorinostat prostate cancer sensitive detail...
PTEN del Gedatolisib prostate cancer sensitive detail...
ATM mutant Olaparib prostate cancer sensitive detail...
ATM inact mut Olaparib prostate cancer sensitive detail...
PTEN loss AZD8186 prostate cancer sensitive detail...
PTEN del AZD8186 prostate cancer predicted - sensitive detail...
PTEN loss Panulisib prostate cancer sensitive detail...
PTEN loss MK2206 prostate cancer no benefit detail...
PTEN loss OP449 prostate cancer sensitive detail...
PTEN loss KU-60019 prostate cancer sensitive detail...
PTEN loss AT13148 prostate cancer sensitive detail...
PTEN A126G Alpelisib prostate cancer sensitive detail...
PTEN A126G AZD6482 prostate cancer sensitive detail...
PTEN loss AZD6482 prostate cancer sensitive detail...
PTEN loss GSK2636771 prostate cancer sensitive detail...
TP53 P223L TP53 V274F Ganetespib prostate cancer resistant detail...
PTEN del Alpelisib + AZD8186 prostate cancer sensitive detail...
PTEN del Alpelisib + AZD8186 + Enzalutamide prostate cancer sensitive detail...
PTEN del AZD8186 + Enzalutamide prostate cancer sensitive detail...
PIK3CA mut PTEN loss PKI-179 prostate cancer sensitive detail...
PTEN loss Acalisib prostate cancer sensitive detail...
PTEN del Ipatasertib prostate cancer sensitive detail...
PTEN loss CX-6258 prostate cancer predicted - sensitive detail...
PTEN loss CX-5461 + CX-6258 prostate cancer predicted - sensitive detail...
PTEN loss CX-5461 prostate cancer no benefit detail...
PTEN loss Ipatasertib prostate cancer sensitive detail...
PTEN loss Voxtalisib prostate cancer sensitive detail...
PTEN loss SF1126 prostate cancer sensitive detail...
PTEN loss Capivasertib prostate cancer sensitive detail...
PTEN loss TP53 loss Capivasertib prostate cancer sensitive detail...
PTEN loss AR-mTOR-26 prostate cancer predicted - sensitive detail...
TP53 inact mut Enzalutamide prostate cancer no benefit detail...
TP53 inact mut Abiraterone prostate cancer no benefit detail...
ATM mutant N/A prostate cancer not applicable detail...
CHEK2 mutant N/A prostate cancer not applicable detail...
APC inact mut Abiraterone prostate cancer decreased response detail...
APC inact mut Enzalutamide prostate cancer decreased response detail...
CHEK1 inact mut Olaparib prostate cancer sensitive detail...
CHEK2 inact mut Olaparib prostate cancer sensitive detail...
ATM inact mut Rucaparib prostate cancer no benefit detail...
CHEK2 inact mut Rucaparib prostate cancer no benefit detail...
RAD51B rearrange Rucaparib prostate cancer predicted - sensitive detail...
PTEN negative Niraparib prostate cancer not predictive detail...
BRAF fusion Trametinib prostate cancer no benefit detail...
BRAF G466A Trametinib prostate cancer no benefit detail...
BRAF D594G Trametinib prostate cancer no benefit detail...
RAD51B inact mut Olaparib prostate cancer sensitive detail...
RAD54L inact mut Olaparib prostate cancer sensitive detail...
RAD51C inact mut Olaparib prostate cancer sensitive detail...
RAD51D inact mut Olaparib prostate cancer sensitive detail...
ATM del Berzosertib prostate cancer sensitive detail...
ATM del Olaparib prostate cancer no benefit detail...
ATM del Rucaparib prostate cancer no benefit detail...
PTEN del PX-866 prostate cancer not predictive detail...
BRAF L597R PLX8394 prostate cancer sensitive detail...
RB1 positive Palbociclib prostate cancer no benefit detail...
PTEN del RER prostate cancer sensitive detail...
PTEN loss Carboplatin + Paclitaxel + Sapanisertib prostate cancer predicted - sensitive detail...
CHEK2 inact mut Abiraterone + Niraparib + Prednisone prostate cancer predicted - sensitive detail...
TP53 Y220C PC14586 prostate cancer predicted - sensitive detail...
ATM del PLX038 prostate cancer sensitive detail...
ATM del PLX038 + Talazoparib prostate cancer sensitive detail...
ATM N2875H Olaparib prostate cancer predicted - sensitive detail...
ATM V2288fs Olaparib prostate cancer predicted - sensitive detail...
RB1 del JQ1 prostate cancer sensitive detail...
RB1 del JQ1 + unspecified PD-L1 antibody prostate cancer sensitive detail...
ATM inact mut Enzalutamide + Talazoparib prostate cancer sensitive detail...
ATR inact mut Enzalutamide + Talazoparib prostate cancer sensitive detail...
CHEK2 inact mut Enzalutamide + Talazoparib prostate cancer sensitive detail...
MLH1 inact mut Enzalutamide + Talazoparib prostate cancer sensitive detail...
RAD51C inact mut Enzalutamide + Talazoparib prostate cancer sensitive detail...
ATM R3008H RP-3500 prostate cancer predicted - sensitive detail...
ATM inact mut Ceralasertib prostate cancer no benefit detail...
ATM negative Ceralasertib prostate cancer no benefit detail...
ATM inact mut unspecified PARP inhibitor prostate cancer no benefit detail...
CHEK2 inact mut unspecified PARP inhibitor prostate cancer no benefit detail...
BRAF L597R PF-07799933 prostate cancer predicted - sensitive detail...
PTEN loss Ipatasertib + Onvansertib prostate cancer sensitive detail...
ATM inact mut Abiraterone + Olaparib + Prednisone prostate cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00313599 Phase I Lapatinib + Paclitaxel Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed USA 0
NCT00670046 Phase II Valproic acid Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer Terminated USA 0
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed USA 0
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed USA 1
NCT01254864 Phase II Abiraterone + Sunitinib Abiraterone + Dasatinib Maximum Androgen Depletion Completed USA 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA | GBR 0
NCT01353625 Phase I CC-115 Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. Completed USA | FRA | ESP | DEU 0
NCT01436968 Phase III Valacyclovir AdV-tk + Valacyclovir Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03) Active, not recruiting USA 1
NCT01480154 Phase I Hydroxychloroquine + MK2206 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Active, not recruiting USA 0
NCT01517802 Phase III Abiraterone A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Completed USA | SWE | GBR | ESP | DEU | BEL | AUS 0
NCT01530984 Phase II Sargramostim Ipilimumab Ipilimumab and GMCSF Immunotherapy for Prostate Cancer Withdrawn USA 0
NCT01540526 Phase I Axitinib Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib Completed USA 0
NCT01543776 Phase II Abiraterone Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer Completed USA 1
NCT01553188 Phase II Prednisone Abiraterone Trebananib AMG 386 and Abiraterone for Advanced Prostate Cancer Completed USA 0
NCT01576172 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT01587703 Phase I Molibresib A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Completed USA | NLD | GBR | FRA | ESP | AUS 1
NCT01607905 Phase I Selinexor Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer Completed USA | DNK | CAN 0
NCT01620593 Phase II Metformin Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer Completed USA 0
NCT01674270 Phase II Bicalutamide Degarelix Degarelix Neo-Adjuvant Radical Prostatectomy Trial Completed CAN 0
NCT01683994 Phase I Cabozantinib + Docetaxel Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Completed USA 0
NCT01685125 Phase II Dasatinib Abiraterone Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Unknown status USA 0
NCT01715285 Phase III Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Completed TUR | SWE | SVK | ROU | POL | NZL | NLD | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG 11
NCT01717053 Phase II Leuprolide Abiraterone Prednisone Goserelin Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer Completed USA 0
NCT01730118 Phase I HER2 Vaccine Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing Completed USA 0
NCT01741753 Phase I Abiraterone + Buparlisib + Prednisone BKM120+Abiraterone Acetate for Metastatic CRPC Terminated USA 0
NCT01751451 Phase II Abiraterone Degarelix 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Completed USA 0
NCT01809691 Phase III Orteronel Bicalutamide S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Active, not recruiting USA 0
NCT01818986 Phase II Sipuleucel-T Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) Completed USA 0
NCT01828476 Phase II Hydroxychloroquine Abiraterone + Navitoclax Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer Terminated USA 0
NCT01834651 Phase II Cabozantinib A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases Completed USA 0
NCT01864096 Phase III Metformin The Metformin Active Surveillance Trial (MAST) Study Active, not recruiting CAN 0
NCT01867333 Phase II PROSTVAC-F-TRICOM Enzalutamide Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer Completed USA 0
NCT01875250 Phase II Enzalutamide + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer Completed USA 0
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Completed USA | GBR | ESP | CAN 0
NCT01913106 Phase Ib/II AdV-tk + Valacyclovir HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer Recruiting USA 0
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Completed USA | ITA | GBR | ESP | CAN 0
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed USA | NLD | AUS 0
NCT01972217 Phase II Prednisone Abiraterone Olaparib Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer Completed USA | POL | NLD | ITA | GBR | FRA | ESP | CZE | CAN | BEL 1
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed USA 0
NCT01990196 Phase II Dasatinib Trametinib Degarelix + Enzalutamide Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Active, not recruiting USA 0
NCT01994590 Phase II Dovitinib Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Terminated USA 0
NCT02009449 Phase I Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors Completed USA 0
NCT02012296 Phase Ib/II Mifepristone Enzalutamide Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer Completed USA 0
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed USA 0
NCT02020070 Phase II Ipilimumab Degarelix Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy Active, not recruiting USA 0
NCT02028988 Phase II Enzalutamide Enzalutamide + External Beam Rt For Prostate Completed USA 0
NCT02043665 Phase I Coxsackievirus A21 Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM) Completed USA | GBR | AUS 0
NCT02059213 Phase II Goserelin Palbociclib Bicalutamide Leuprolide A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer Completed USA 0
NCT02091531 Phase II Sapanisertib Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients Completed USA 0
NCT02115828 Phase I Vismodegib A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy Completed USA 0
NCT02159950 Phase II Sipuleucel-T Tasquinimod Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Completed USA 0
NCT02218606 Phase II Cabazitaxel Abiraterone + Prednisone Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer Completed USA 0
NCT02234921 Phase I Cyclophosphamide Pilot Study of DRibble Vaccine for Prostate Cancer Patients Completed USA 0
NCT02259114 Phase I Birabresib A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors Completed 0
NCT02265536 Phase I LY3022855 A Study of LY3022855 In Participants With Breast or Prostate Cancer Completed USA 0
NCT02278185 Phase II Goserelin Degarelix Histrelin acetate Triptorelin Leuprolide Enzalutamide Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer Active, not recruiting USA 0
NCT02279862 Phase II Ipilimumab Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS 1
NCT02312557 Phase II Enzalutamide + Pembrolizumab Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide Active, not recruiting USA 0
NCT02325557 Phase Ib/II Pembrolizumab ADXS31-142 ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046 Completed USA 0
NCT02339168 Phase I Enzalutamide + Metformin Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02366494 Phase I Leuprolide Goserelin Triptorelin Bicalutamide Docetaxel Micro RNAs to Predict Response to Androgen Deprivation Therapy Completed USA 0
NCT02403505 Phase II Enzalutamide Abiraterone Prednisone Degarelix Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms Active, not recruiting USA 0
NCT02420652 Phase II Metformin Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy Terminated USA 0
NCT02429193 Phase II Enzalutamide Abiraterone + Prednisone Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) Completed CAN 0
NCT02430480 Phase II Goserelin Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer Active, not recruiting USA 0
NCT02438007 Phase III Galeterone Enzalutamide A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC Terminated USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS 0
NCT02452008 Phase II Galunisertib Enzalutamide Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT02489357 Phase I Degarelix Pembrolizumab Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer Completed USA 0
NCT02494921 Phase Ib/II Docetaxel + Filgrastim + Prednisone + Ribociclib LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC Completed USA 0
NCT02507570 Phase II Enzalutamide Radium Ra 223 dichloride Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis Completed USA 0
NCT02522715 Phase Ib/II Cabazitaxel + Enzalutamide Prednisone Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02531516 Phase III Abiraterone + Apalutamide + Prednisone Bicalutamide An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy Active, not recruiting USA | TUR | SWE | ROU | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | ARG 7
NCT02555189 Phase Ib/II Ribociclib Enzalutamide Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression Completed USA 0
NCT02566772 Phase I TAS3681 Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer Completed USA | GBR | FRA | ESP 0
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed FRA | ESP | DNK 0
NCT02594072 Phase I Goserelin Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT) Active, not recruiting CAN 0
NCT02607228 Phase Ib/II Enzalutamide Exemestane + GS-5829 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer Terminated USA 0
NCT02614859 Phase II Bicalutamide Metformin Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients Completed USA 0
NCT02616185 Phase I PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) Terminated USA 0
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN | AUS 0
NCT02660034 Phase I Pamiparib + Tislelizumab The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed USA | NZL | GBR | FRA | ESP | AUS 0
NCT02663908 Phase III Degarelix Leuprolide A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease Terminated USA | SVK | POL | GRC | GBR | FRA | FIN | DEU | CZE | CAN 2
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated 0
NCT02705469 Phase I ZEN-3694 A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT02711956 Phase I Enzalutamide + ZEN-3694 A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT02721433 FDA approved Denosumab + pamidronate + Zoledronic acid 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) Completed CAN 0
NCT02744287 Phase Ib/II BPX-601 + Rimiducid Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors Suspended USA 0
NCT02766478 Phase II Genistein Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer Terminated USA 0
NCT02796898 Phase Ib/II SM88 Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer Completed USA 0
NCT02807805 Phase II Abiraterone + Niclosamide + Prednisone Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02833883 Phase I CC-115 + Enzalutamide Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer Completed USA 0
NCT02854436 Phase II Niraparib An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies Completed USA | SWE | NLD | ISR | GBR | FRA | ESP | DNK | CAN | BRA | BEL | AUS 3
NCT02881242 Phase II Trametinib Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer Active, not recruiting USA 0
NCT02887976 Phase III Abiraterone + Methylprednisolone Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 Completed USA 0
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Terminated USA | ITA | FRA | ESP | DEU | CAN 4
NCT02924766 Phase I Apalutamide + Niraparib A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) Completed USA | CAN 0
NCT02933255 Phase Ib/II Ipilimumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Ipilimumab + Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Nivolumab + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer Completed USA 0
NCT02935205 Phase Ib/II Enzalutamide + Indomethacin Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer Recruiting USA 0
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Completed USA | ITA | DEU | CHE | CAN | AUT 3
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Unknown status USA 0
NCT02960022 Phase II Abiraterone + Enzalutamide + Prednisone Enzalutamide A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Recruiting USA | TUR | SWE | SVK | ROU | POL | NZL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 13
NCT02966587 Phase II Durvalumab Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Withdrawn USA 0
NCT02972060 Phase II Triptorelin Leuprolide Degarelix Goserelin Darolutamide ODM-201 vs Androgen Deprivation Therapy in Hormone naive Prostate Cancer Active, not recruiting ITA | FRA | ESP | BEL 0
NCT02985957 Phase II Ipilimumab + Nivolumab A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | POL | ITA | FRA | ESP | DNK | DEU | CAN | AUT | AUS 0
NCT02987543 Phase III Olaparib Enzalutamide Abiraterone Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) Completed USA | TUR | SWE | NOR | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUT | AUS | ARG 3
NCT03016741 FDA approved Enzalutamide Abiraterone + Prednisone Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Unknown status USA 0
NCT03067051 Phase I Verteporfin Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System Recruiting USA | SWE | GBR | CAN 0
NCT03088124 Phase II Apalutamide Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PC-ARN) Unknown status FRA 0
NCT03089203 Phase I CART-PSMA-TGF-beta RDN Cyclophosphamide + Fludarabine CART-PSMA-TGFbetaRDN Cells for Castrate-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03098160 Phase I Evofosfamide + Ipilimumab Immunotherapy Study of Evofosfamide in Combination With Ipilimumab Unknown status USA 0
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Completed USA 3
NCT03120832 Phase I PAN-301-1 Phase 1 Trial of PAN-301-1 in Cancer Patients Completed USA 0
NCT03123978 Phase I Enzalutamide + Niclosamide Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT03141671 Phase II Bicalutamide + Gonadorelin Abiraterone + Apalutamide + Gonadorelin + Prednisone Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) Active, not recruiting USA 0
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors Completed USA | GBR | ESP | AUS 0
NCT03179410 Phase II Avelumab PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC) Completed USA 0
NCT03188965 Phase I Elimusertib First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Completed USA | GBR | CHE | CAN 3
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Completed USA 0
NCT03217747 Phase Ib/II Avelumab + PF-04518600 + Utomilumab Avelumab + Utomilumab Avelumab + PF-04518600 Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies Active, not recruiting USA 0
NCT03264664 Phase I E7386 Study of E7386 in Participants With Selected Advanced Neoplasms Active, not recruiting USA | GBR 0
NCT03311555 Phase II Apalutamide + Docetaxel A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) Completed USA 0
NCT03315871 Phase II Bintrafusp alfa + CV301 + PROSTVAC-F-TRICOM + PROSTVAC-V-TRICOM Combination Immunotherapy in Biochemically Recurrent Prostate Cancer Active, not recruiting USA 0
NCT03325127 Phase I Abiraterone + Enzalutamide + Radium Ra 223 dichloride Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study Withdrawn 0
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Terminated USA | HUN | GBR | DNK | CAN | BEL | AUS 2
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03344211 Phase II Enzalutamide + Radium Ra 223 dichloride Enzalutamide Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03358563 Phase I Bicalutamide + Degarelix + Docetaxel Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer Completed USA 0
NCT03360006 Phase I ABBV-744 A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer Terminated USA 0
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Terminated USA | CAN 0
NCT03363893 Phase Ib/II Samuraciclib Fulvestrant + Samuraciclib Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies Completed USA | GBR 0
NCT03367819 Phase Ib/II Isatuximab Cemiplimab + Isatuximab Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies Terminated USA | ITA | GBR | FRA 1
NCT03409458 Phase Ib/II Avelumab + Imifoplatin A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Completed USA | CHE 0
NCT03418324 Phase II Abiraterone + Carotuximab Carotuximab + Enzalutamide Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy Completed USA 0
NCT03436485 Phase Ib/II ODM-208 Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) Active, not recruiting USA | GBR | FRA | FIN 0
NCT03450109 Phase I LY01005 Goserelin A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX) in Patients With Prostate Cancer Completed USA 0
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers Completed USA | AUS 0
NCT03460977 Phase I PF-06821497 PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting USA | POL | ESP | BGR 4
NCT03473925 Phase II Navarixin + Pembrolizumab Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed USA | ISR | CAN | AUS 1
NCT03477864 Phase I Ipilimumab Cemiplimab + Ipilimumab Cemiplimab Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer Withdrawn 0
NCT03478904 Phase I Enzalutamide Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer Terminated USA 0
NCT03481816 Phase I ETBX-051 + ETBX-061 + ETBX-071 Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Completed USA 0
NCT03493945 Phase Ib/II Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + Nogapendekin alfa inbakicept Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). Completed USA 0
NCT03507608 Phase I Flutamide Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression Active, not recruiting USA 0
NCT03511664 Phase III lutetium Lu 177 vipivotide tetraxetan Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION) Completed USA | SWE | NLD | GBR | FRA | DNK | DEU | CAN | BEL 1
NCT03517969 Phase II Carboplatin + Docetaxel Berzosertib + Carboplatin ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA 0
NCT03518606 Phase Ib/II Durvalumab + Tremelimumab + Vinorelbine Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours (MOVIE) Active, not recruiting FRA 0
NCT03531827 Phase II Enzalutamide + NLG207 Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Terminated USA 0
NCT03543189 Phase Ib/II Nivolumab Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy Active, not recruiting USA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 1
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Completed USA | ITA | GBR | ESP | CAN 4
NCT03568539 Phase Ib/II Sintilimab IBI308 in Subjects With Advanced/Metastatic Solid Malignancies Completed USA 0
NCT03568656 Phase Ib/II Atezolizumab + CCS1477 CCS1477 CCS1477 + Olaparib CCS1477 + Darolutamide Abiraterone + CCS1477 CCS1477 + Enzalutamide Study to Evaluate CCS1477 in Advanced Tumours Recruiting USA | SWE | NLD | GBR | FRA | ESP 0
NCT03572478 Phase Ib/II Nivolumab + Rucaparib Nivolumab Rucaparib Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer Terminated USA 0
NCT03575819 Phase I FOR46 A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Completed USA 0
NCT03592264 Phase Ib/II OBI-3424 This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer Terminated USA 0
NCT03673787 Phase Ib/II Atezolizumab + Ipatasertib A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP) Unknown status GBR 0
NCT03674814 Phase I Enzalutamide + Relacorilant Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer Active, not recruiting USA 0
NCT03685591 Phase I PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Terminated USA 0
NCT03689699 Phase II BMS-986253 + Degarelix + Nivolumab Degarelix + Nivolumab Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) Active, not recruiting USA 0
NCT03709550 Phase Ib/II Decitabine + Enzalutamide Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Withdrawn USA 0
NCT03751436 Phase Ib/II Enzalutamide + Venetoclax Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Completed USA 0
NCT03761225 Phase III Docetaxel + Prednisone Docetaxel + Masitinib + Prednisone Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer Completed ITA | FRA | CAN 3
NCT03777982 Phase III Abiraterone + Apalutamide + Prednisone A Randomized Phase III Study - Conventional ADT w/ or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT Terminated USA 0
NCT03784677 Phase I SOR-C13 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors Completed USA 0
NCT03792841 Phase I AMG 160 + Pembrolizumab AMG 160 Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With mCRPC Completed USA | NLD | FRA | CAN | BEL | AUT | AUS 3
NCT03799003 Phase I ASP1951 A Study of ASP1951 in Subjects With Advanced Solid Tumors Terminated USA | CAN 2
NCT03810105 Phase II Durvalumab + Olaparib A Study of Olaparib and Durvalumab in Prostate Cancer Terminated USA 0
NCT03811652 Phase I MEDI7247 A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Completed USA | CAN 0
NCT03835533 Phase I CDX-301 + INO-5151 + Nivolumab CDX-301 + Nivolumab + Poly ICLC Nivolumab + NKTR-214 Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations (PORTER) Completed USA 0
NCT03850795 Phase III Enzalutamide HC-1119 HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Terminated USA | POL | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CAN | AUT | AUS 1
NCT03860987 Phase II Abiraterone + Enzalutamide + Goserelin + Prednisone Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Active, not recruiting USA 0
NCT03873805 Phase I Cyclophosphamide + Fludarabine Anti-PSCA(dCH2)BBz-CAR-T cells PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer Active, not recruiting USA 0
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Terminated USA 0
NCT03899467 Phase II Proxalutamide the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer Completed USA 0
NCT03934840 Phase II Abiraterone + Cabazitaxel + Carboplatin + Prednisone Phase 2 of Carbo, Taxel and Abi in Metastatic Castration Prostate Cancer Active, not recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL | AUS 1
NCT03951831 Phase II Cemiplimab + Degarelix + Docetaxel + Leuprolide REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer Active, not recruiting USA 0
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Suspended USA 0
NCT04009967 Phase II Pembrolizumab Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning (PICT-01) Active, not recruiting CAN 0
NCT04019964 Phase II Nivolumab Nivolumab in Biochemically Recurrent dMMR Prostate Cancer Recruiting USA 0
NCT04030559 Phase II Niraparib Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects Recruiting USA 0
NCT04038502 Phase II Olaparib Carboplatin Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA) Recruiting USA 0
NCT04052204 Phase II Avelumab + NKTR-214 Avelumab + NKTR-214 + Talazoparib Avelumab + Enzalutamide + NKTR-214 Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors Terminated USA | POL | ESP | BEL 0
NCT04052971 Phase Ib/II ABN401 To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation Recruiting AUS 1
NCT04060342 Phase Ib/II GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma Terminated USA | GBR 0
NCT04068896 Phase I NGM120 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy Completed USA 0
NCT04071236 Phase Ib/II Peposertib + Radium Ra 223 dichloride Radium Ra 223 dichloride Avelumab + Peposertib + Radium Ra 223 dichloride Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Recruiting USA 0
NCT04087174 Phase I Abiraterone + Capivasertib Capivasertib + Enzalutamide A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer Completed USA | ESP 0
NCT04089553 Phase II AZD4635 + Durvalumab AZD4635 + Oleclumab An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer Completed USA 0
NCT04095273 Phase I Elimusertib + Pembrolizumab Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Completed USA | GBR | ESP | DEU | CHE 0
NCT04104607 Phase I CC-1 the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (PSMAxCD3) Recruiting DEU 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04143789 Phase Ib/II AP-002 Evaluation of AP-002 in Patients With Solid Tumors Unknown status USA 0
NCT04145375 Phase Ib/II Enzalutamide + ZEN-3694 Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol Enrolling by invitation USA 0
NCT04145622 Phase Ib/II Ifinatamab deruxtecan Study of DS-7300a in Participants With Advanced Solid Malignant Tumors Recruiting USA 1
NCT04148937 Phase I LY3475070 LY3475070 + Pembrolizumab A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Completed USA | GBR | AUS 0
NCT04157517 Phase I TAK-573 A Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics Study Completed USA | AUS 0
NCT04159896 Phase II CEP-11981 + Nivolumab ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT04169841 Phase II Durvalumab + Olaparib + Tremelimumab Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) Active, not recruiting FRA 0
NCT04182516 Phase I NMS-03305293 Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors Terminated USA | ITA | GBR | BGR 1
NCT04207255 Phase II ABC294640 + Enzalutamide ABC294640 + Abiraterone Addition of Opaganib to Androgen Antagonists in Patients With mCRPC Completed USA 0
NCT04221542 Phase I AMG 509 + Dexamethasone Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting USA | ESP | DEU | CHE | AUS 5
NCT04243499 Phase I ICT01 First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) Recruiting USA | GBR | FRA | ESP | DEU | BEL 0
NCT04249947 Phase I P-PSMA-101 CAR-T cells Rimiducid P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Active, not recruiting USA 0
NCT04250597 Phase I GNX102 Study of GNX102 in Patients With Advanced Solid Tumors Terminated USA 1
NCT04253262 Phase Ib/II Copanlisib + Rucaparib A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT04267887 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide, Abiraterone Acetate, and Prednisone for the Treatment of Metastatic High Risk Castration Sensitive Prostate Cancer Active, not recruiting USA 0
NCT04276376 Phase II Atezolizumab + Rucaparib Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Suspended FRA 0
NCT04337099 Expanded access Tempol A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer Available USA 0
NCT04337580 Phase II Cabazitaxel + Omeprazole Docetaxel + Omeprazole Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (FASN) Recruiting USA 0
NCT04343885 Phase II Docetaxel Docetaxel + lutetium Lu 177 vipivotide tetraxetan In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA) Active, not recruiting AUS 0
NCT04367675 Phase I INO-5401 INO-5401 + INO-9012 INO 5401 Vaccination in BRCA1/2 Mutation Carriers Recruiting USA 0
NCT04381832 Phase Ib/II Enzalutamide + Etrumadenant + Zimberelimab Docetaxel + Etrumadenant + Zimberelimab AB680 + Etrumadenant + Zimberelimab AB680 + Etrumadenant Enzalutamide Docetaxel Etrumadenant + Zimberelimab Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6) Completed USA | CAN 0
NCT04408924 Phase II Abemaciclib Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer (CYCLONE 1) Completed USA | FRA | ESP 0
NCT04419402 Phase II Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Enzalutamide Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p) Active, not recruiting AUS 0
NCT04421222 Phase I EPI-7386 Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer (EPI-7386) Active, not recruiting USA | CAN 0
NCT04423029 Phase Ib/II DF6002 DF6002 + Nivolumab A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors Recruiting USA | FRA | ESP | AUS 0
NCT04424641 Phase Ib/II GEN1044 A Study on the Safety of GEN1044 (DuoBody-CD3x5T4) in Subjects With Malignant Solid Tumors Terminated USA | ISR | ESP | DNK 0
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04434482 Phase I Senaparib + Temozolomide IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer Completed USA | AUS 3
NCT04477512 Phase I Abiraterone + Cabozantinib + Nivolumab + Prednisone Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) Active, not recruiting USA 0
NCT04478279 Phase Ib/II ST-101 A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors Active, not recruiting USA | GBR 0
NCT04484818 Phase III Goserelin Leuprolide Darolutamide + Leuprolide Darolutamide + Triptorelin Triptorelin Darolutamide + Goserelin Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Active, not recruiting USA 0
NCT04550494 Phase II Talazoparib Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Recruiting USA 0
NCT04564027 Phase II Ceralasertib A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer Active, not recruiting USA | FRA | ESP 0
NCT04565496 Phase II Pembrolizumab Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients (PEM-PRO) Unknown status ITA 0
NCT04575766 Phase I FT-7051 A Study of FT-7051 in Men With MCRPC Terminated USA 0
NCT04580485 Phase I INCB106385 + Retifanlimab INCB106385 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT04585932 Phase II Apalutamide + Degarelix Apalutamide + Leuprolide Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Withdrawn USA 0
NCT04606446 Phase I PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) Recruiting USA | AUS 3
NCT04633252 Phase Ib/II Docetaxel + NHS-IL12 Bintrafusp alfa + Degarelix + Docetaxel + NHS-IL12 + Prednisone Degarelix + Docetaxel + NHS-IL12 + Prednisone Bintrafusp alfa + Docetaxel + NHS-IL12 Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer Recruiting USA 0
NCT04663997 Phase II Docetaxel lutetium Lu 177 vipivotide tetraxetan 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer Active, not recruiting CAN 0
NCT04676334 Phase III Rucaparib CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) Completed POL | ITA | ISR | GBR | CAN 1
NCT04677855 Phase I Dutasteride + PCUR-101 PCUR-101 Abiraterone + PCUR-101 + Prednisone Study of PCUR-101 in Combination With ADT in Patients With mCRPC Terminated USA | AUS 0
NCT04703920 Phase I Belinostat + Talazoparib Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer Active, not recruiting USA 0
NCT04706962 Phase I TH1902 TH1902 in Patients With Advanced Solid Tumors Recruiting USA | CAN 0
NCT04709276 Phase II Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) Recruiting USA 0
NCT04729114 Phase Ib/II PRL-02 Open-label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer Recruiting USA 0
NCT04737109 Phase Ib/II Darolutamide + Ipatasertib Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer Terminated USA 0
NCT04787744 Phase II Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) Recruiting USA 0
NCT04821622 Phase III Enzalutamide Enzalutamide + Talazoparib Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Active, not recruiting USA | TUR | SVK | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BGR | BEL | AUS | ARG 9
NCT04839991 Phase I CB307 Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) Recruiting USA | NLD | GBR | ESP 0
NCT04843319 Phase Ib/II VERU-100 To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer (VERU-100) Terminated USA 0
NCT04846478 Phase I Talazoparib + Tazemetostat Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC Active, not recruiting USA 0
NCT04848337 Phase II Lenvatinib + Pembrolizumab Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC) Recruiting USA 0
NCT04876755 Phase II Tempol MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer Unknown status USA 0
NCT04890613 Phase I CX-5461 Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Recruiting USA | CAN 0
NCT04925648 Phase II Darolutamide + Dasatinib Dasatinib Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO) Recruiting AUS 0
NCT04943536 Phase I Biolen Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer (Biolen + RT) Recruiting USA 0
NCT04957290 Phase Ib/II NOX66 A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors Terminated USA 0
NCT04969315 Phase Ib/II TT-10 TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors Active, not recruiting USA 0
NCT04970992 Phase I DZ-002 A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma Recruiting USA 0
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT04986423 Phase II Enzalutamide + ZEN-3694 Enzalutamide ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer Recruiting USA 1
NCT05000294 Phase Ib/II Atezolizumab + Tivozanib Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types Recruiting USA 0
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA | ISR 0
NCT05032040 Phase II XmAb20717 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies Recruiting USA 0
NCT05036226 Phase Ib/II Hydroxychloroquine + Metformin + Sirolimus Dasatinib + Hydroxychloroquine + Metformin + Nelfinavir + Sirolimus Hydroxychloroquine + Metformin + Nelfinavir + Sirolimus Dasatinib + Hydroxychloroquine + Metformin + Sirolimus COAST Therapy in Advanced Solid Tumors and Prostate Cancer (COAST) Recruiting USA 0
NCT05037500 Phase I Decitabine and Cedazuridine + Enzalutamide Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer Active, not recruiting USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Active, not recruiting USA 0
NCT05057013 Phase Ib/II HMBD-001 HMBD-001 in Advanced HER3 Positive Solid Tumours Recruiting GBR 0
NCT05084859 Phase I Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors Terminated USA | AUS 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Terminated NLD | FRA 0
NCT05104515 Phase I OVM-200 First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine Recruiting GBR 0
NCT05107674 Phase I NX-1607 A Study of NX-1607 in Adults With Advanced Malignancies Recruiting USA | GBR 0
NCT05113537 Phase Ib/II Abemaciclib + lutetium Lu 177 vipivotide tetraxetan Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer (UPLIFT) Recruiting USA 0
NCT05150236 Phase II Ipilimumab + lutetium Lu 177 vipivotide tetraxetan + Nivolumab lutetium Lu 177 vipivotide tetraxetan Nivolumab 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC (EVOLUTION) (EVOLUTION) Active, not recruiting AUS 0
NCT05159518 Phase I PRT2527 A Study of PRT2527 in Participants With Advanced Solid Tumors Completed USA 0
NCT05169112 Phase III Leuprolide Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy Recruiting CAN 0
NCT05177770 Phase II Etrumadenant + SRF617 + Zimberelimab Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer Terminated USA | CAN 0
NCT05189457 Phase II Docetaxel + Triptorelin Degarelix + Enzalutamide Enzalutamide + Triptorelin Docetaxel + Leuprolide Docetaxel + Relugolix Docetaxel + Goserelin Degarelix + Docetaxel Enzalutamide + Relugolix Enzalutamide + Goserelin Abiraterone + Leuprolide Docetaxel + Tislelizumab Enzalutamide + Leuprolide Abiraterone + Goserelin Abiraterone + Triptorelin Abiraterone + Degarelix Abiraterone + Relugolix First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer Active, not recruiting USA 0
NCT05191017 Phase Ib/II Enzalutamide + NUV-422 Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC Withdrawn USA 0
NCT05191680 Phase III Apalutamide TherApeutics in Early ProState Cancer (TAPS02) Recruiting GBR 0
NCT05241613 Phase I AC176 A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer Terminated USA 0
NCT05252390 Phase Ib/II NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT05256381 Phase II Pembrolizumab + SOT101 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors Active, not recruiting USA | POL | ITA | HUN | FRA | ESP | CZE | BEL 1
NCT05272709 Phase Ib/II TT-702 TT-702 in Patients With Advanced Solid Tumours. (CURATE) Recruiting GBR 0
NCT05276492 Phase I Abiraterone + Prednisone Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Active, not recruiting USA 0
NCT05293496 Phase I MGC018 + MGD019 A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors Active, not recruiting USA 0
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Completed USA | ESP | BEL | ARG 2
NCT05307874 Phase Ib/II Aldesleukin + ICT01 Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) Recruiting FRA 0
NCT05346848 Phase II Darolutamide A Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer (DARIUS) Recruiting FRA 0
NCT05358379 Phase Ib/II CYC140 A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma Recruiting USA | ESP 1
NCT05361798 Phase II NHS-IL12 T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy Recruiting USA 0
NCT05361915 Phase II Abiraterone + Abivertinib Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer Suspended USA 0
NCT05367440 Phase Ib/II Darolutamide + Saruparib Abiraterone + Saruparib Enzalutamide + Saruparib Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Recruiting USA | ITA | GBR | AUS 0
NCT05369000 Phase Ib/II LAVA-1207 Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer Recruiting USA | NLD | ESP 0
NCT05383079 Phase Ib/II Lutetium-177 PSMA-I&T Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men With Metastatic Castration-Resistant Prostate Cancer: Phase I/II Study (AlphaBet) Recruiting AUS 0
NCT05394103 Phase Ib/II Q901 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors Recruiting USA 1
NCT05413421 Phase I ORIC-944 Study of ORIC-944 in Patients With Metastatic Prostate Cancer Recruiting USA | GBR | ESP | AUS 0
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05417594 Phase Ib/II AZD9574 AZD9574 + Temozolomide Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) Recruiting USA | SWE | GBR | ESP | DEU | AUS 1
NCT05420636 Phase II ORY-1001 + Paclitaxel Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Recruiting USA 0
NCT05445882 Phase II Bintrafusp alfa + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer Withdrawn USA 0
NCT05458856 Phase III Triptorelin Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate Completed NLD | LTU | FRA | ESP | DEU | CZE | BEL 0
NCT05488548 Phase I NEO2734 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors Recruiting USA 0
NCT05534646 Phase II Apalutamide Apalutamide + Carotuximab Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05567679 Phase I Tazemetostat A Study of Tazemetostat (Tazverik) Before Prostatectomy in Men With Prostate Cancer Withdrawn USA 0
NCT05592626 Phase Ib/II STAR0602 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) Recruiting USA | FRA | ESP | CAN 0
NCT05642780 Phase II Pembrolizumab + SKB264 SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors Recruiting USA | POL | CAN | BEL | AUS 1
NCT05642949 Phase Ib/II MHB036C Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05652855 Phase Ib/II MHB088C Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors Not yet recruiting AUS 0
NCT05662397 Phase Ib/II HST-1011 Cemiplimab + HST-1011 A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody Recruiting USA 0
NCT05679388 Phase I Relugolix Itraconazole + Relugolix Relugolix + Ritonavir A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients Terminated USA 0
NCT05683964 Phase I Apalutamide Darolutamide Enzalutamide Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression Recruiting USA 0
NCT05684965 Phase I XTX301 XTX301 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05704985 Phase I DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors Recruiting USA 0
NCT05726292 Phase II Enzalutamide Enzalutamide + Relacorilant A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Recruiting USA 0
NCT05730712 Phase II Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study Recruiting USA 0
NCT05731271 Phase Ib/II TST003 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Active, not recruiting USA 0
NCT05743621 Phase I Enzalutamide + TVB-2640 Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05751941 Phase II Sipuleucel-T Abiraterone + Sipuleucel-T Apalutamide + Sipuleucel-T Enzalutamide + Sipuleucel-T Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer Recruiting USA 0
NCT05762536 Phase II Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) Recruiting NLD 0
NCT05781217 Phase III Bicalutamide + Triptorelin Bicalutamide + Leuprolide Bicalutamide + Goserelin Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624 (URONCOR 06-24) Recruiting ESP 0
NCT05785741 Phase Ib/II DB-1310 A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors Recruiting USA 1
NCT05790213 Phase II Apalutamide Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer Suspended USA 0
NCT05805371 Phase I Anti-PSCA(dCH2)BBz-CAR-T cells PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT05806814 Phase I Sipuleucel-T Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer Recruiting USA 0
NCT05807126 Phase I Hu5F9-G4 + Olaparib Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations Withdrawn USA 0
NCT05828082 Phase II M1774 Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer Recruiting USA 0
NCT05849298 Phase II lutetium Lu 177 vipivotide tetraxetan Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + lutetium Lu 177 vipivotide tetraxetan Apalutamide + lutetium Lu 177 vipivotide tetraxetan A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (PSMACare) Recruiting USA | POL | NLD | ITA | FRA | ESP | CZE | CAN 3
NCT05884398 Phase III Apalutamide A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) Recruiting USA | POL | FRA | DEU | CAN | BRA | AUS 2
NCT05893381 Phase II PNT2002 Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) (LUST) Recruiting ITA 0
NCT05914116 Phase Ib/II DB-1311 A Study of DB-1311 in Advanced/Metastatic Solid Tumors Recruiting USA | AUS 2
NCT05917860 Phase I Degarelix Neoadjuvant ADT With TULSA in the Treatment of Intermediate Risk Prostate Cancer (NeoADT-TULSA) Recruiting FIN 0
NCT05932862 Phase I ISM3091 First-in Human Phase I Study of ISM3091 in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05934539 Phase Ib/II ALG.APV-527 ALG.APV-527 First-in-human Study Recruiting USA 0
NCT05938270 Phase I Darolutamide Darolutamide + Saruparib Saruparib A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN) Recruiting USA | NLD | GBR | ESP | CAN | AUS 0
NCT05944237 Phase Ib/II Atezolizumab + HTL0039732 HTL0039732 HTL0039732 in Participants With Advanced Solid Tumours Recruiting GBR 0
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT05983198 Phase Ib/II 225Ac-PSMA-R2 A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. Recruiting FRA | AUS 0
NCT05985083 Phase I IMM47 A Study Of IMM47 In Subjects With Advanced Solid Tumors Recruiting AUS 0
NCT05997615 Phase Ib/II AMX-500 Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Recruiting GBR | ESP | AUS 0
NCT06014502 Phase I IMGS-001 Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Recruiting USA 0
NCT06033001 Expanded access PNT2002 Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Available USA 0
NCT06046040 Phase I TmPSMA-02 CAR-T cells TmPSMA-02 in mCRPC Recruiting USA 0
NCT06056323 Phase Ib/II HB0045 A Study of HB0045 Injection in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06060587 Phase II Abiraterone Abiraterone + Docetaxel Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone Active, not recruiting USA 0
NCT06096870 Phase II Enzalutamide Enzalutamide + NHS-IL12 Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy Recruiting USA 0
NCT06111781 Phase III Relugolix The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer Recruiting USA 0
NCT06126731 Phase Ib/II Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin Combination Study of Antibiotics With Enzalutamide (PROMIZE) Recruiting GBR | CHE 0
NCT06129851 Phase II Relugolix Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer Not yet recruiting USA 0
NCT06168487 Phase I Telmisartan Telmisartan in Prostate Cancer Recruiting USA 0
NCT06172478 Phase II Patritumab deruxtecan A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting USA 2
NCT06200103 FDA approved lutetium Lu 177 vipivotide tetraxetan Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Recruiting USA 0
NCT06216249 Phase II lutetium Lu 177 vipivotide tetraxetan Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Recruiting USA 0
NCT06218667 Phase Ib/II Copanlisib + Degarelix A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer Withdrawn 0
NCT06220188 Phase II Lutetium-177 PSMA-I&T PSMA-RLT in Biochemically Recurrent PCa Recruiting AUT 0
NCT06228053 Phase II Enzalutamide + SX-682 Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) Recruiting USA 0
NCT06238479 Phase I LY4101174 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Recruiting USA | ESP | BEL | AUS 1
NCT06242470 Phase I MGC026 A Study of MGC026 in Participants With Advanced Solid Tumors Recruiting USA | GBR | AUS 0
NCT06253130 Phase Ib/II IMP1734 A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors Recruiting USA | AUS 2
NCT06259123 Phase II Lutetium-177 PSMA-I&T Neoadjuvant PSMA-RLT in Oligometastatic PCa Recruiting AUT 0
NCT06279130 Phase II Balstilimab Balstilimab + Botensilimab Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) Recruiting NLD 0
NCT06282588 Phase II Docetaxel Leuprolide Degarelix Goserelin Triptorelin Darolutamide Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER) Recruiting BEL 0
NCT06288113 Phase II lutetium Lu 177 vipivotide tetraxetan Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial Recruiting USA 0
NCT06343038 Phase I Lutetium-177 PSMA-I&T 161Tb-SibuDAB Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study (PROGNOSTICS) Recruiting CHE 0
NCT06347705 Phase II 2141 V-11 A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer Recruiting USA 0
NCT06378866 Phase II Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) Recruiting USA 0
NCT06395753 Phase II Debio 4228 A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer Recruiting USA | FRA | ESP | BEL 0
NCT06397703 Phase III Leuprolide Degarelix Relugolix ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer Recruiting USA 0
NCT06399757 Phase Ib/II APL-5125 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06451497 Phase I ZM008 Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06458712 Phase I DSB2455 Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies Recruiting ESP 0
NCT06463457 Phase II Darolutamide + Relugolix Comeback From Long coursE ADT With RElugolix and Darolutamide (CLEARED) Recruiting USA 0
NCT06465069 Phase I LY4052031 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) Recruiting USA | GBR | ESP 1
NCT06526299 Phase II lutetium Lu 177 vipivotide tetraxetan Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease Not yet recruiting USA 0
NCT06545942 Phase I MOMA-313 + Olaparib MOMA-313 Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT06548672 Phase I BC3195 A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer Recruiting USA 0
NCT06582017 Phase I QXL138AM Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma Recruiting USA 0
NCT06630325 Phase II Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Not yet recruiting USA 0
NCT06634849 Phase Ib/II PTT-4256 An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. Recruiting AUS 0
NCT06636123 Phase I GZ17-6.02 GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy Not yet recruiting USA 0
NCT06636682 Phase II FK-PC101 FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer Recruiting USA 0